Credit Suisse Ag Lineage Cell Therapeutics, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $25,289 - $51,832	-20,900 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $38,456 - $56,012	20,900 New	20,900 $51,000
Q1 2021 May 14, 2021	SELL	$1.77 - $3.1 $26,550 - $46,500	-15,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$0.95 - $1.83 $14,250 - $27,450	15,000 New	15,000 $26,000
Q4 2019 Feb 12, 2020	SELL	$0.54 - $1.01 $14,764 - $27,615	-27,342 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$0.85 - $1.24 $23,240 - $33,904	27,342 New	27,342 $27,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.